All In Biotech

Drug Trial Radar · NCT04058353

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Last checked: Nov 19, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

271

Actual

Start

Aug 28, 2019

Primary completion

Jun 12, 2020

Study completion Jun 12, 2020

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Aug 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).

Conditions

  • Cystic Fibrosis

Interventions

  • ELX/TEZ/IVADrug

    FDC tablet for oral administration.

  • IVADrug

    Mono-tablet for oral administration.

  • TEZ/IVADrug

    Fixed-dose combination (FDC) tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for ELX/TEZ/IVA GroupTime frame: From Baseline Through Week 8

Locations

93 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner University of Arizona Medical Center

    Tucson, Arizona

  • Miller Children's Hospital / Long Beach Memorial

    Long Beach, California

  • Stanford University

    Palo Alto, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California San Francisco, Lung Transplant Program

    San Francisco, California

  • National Jewish Health

    Denver, Colorado

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Central Florida Pulmonary Group, PA

    Orlando, Florida

  • Indiana University

    Indianapolis, Indiana

  • The University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Michigan Medicine

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine / St. Louis Children's Hospital

    St Louis, Missouri

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Northwell Health- Long Island Jewish Medical Center

    New Hyde Park, New York

  • Mount Sinai Beth Israel

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • University of North Carolina Hospitals

    Chapel Hill, North Carolina

  • UC Health Holmes

    Cincinnati, Ohio

  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center

    Toledo, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Dell Children's Medical Group

    Austin, Texas

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • Texas Children's Hospital

    Houston, Texas

  • University of Utah / Primary Children's Medical Center

    Salt Lake City, Utah

  • University of Washington Medical Center

    Seattle, Washington

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

  • The Prince Charles Hospital

    Chermside, Australia

  • Alfred Hospital

    Melbourne, VIC, Australia

  • Perth Children's Hospital

    Nedlands, Australia

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.